个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：

收录情况： ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：领军期刊 ◇ 中华系列

作者：
Liu Jiaye[1,2,3,4] ; Tian Ye[5] ; Fu Xia[6] ; Mu Chunyang[7] ; Yao Menglin[4] ; Ni Yinyun[4] ; Liu Yong[8,*1] ; Li Zhihui[1,2] ;
机构： [1]Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China. [2]Laboratory of Thyroid and Parathyroid Diseases, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China. [3]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan 610000, China. [4]Respiratory Health Institute, Frontiers Science Center for Disease Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China. [5]Department of Ultrasound, West China Hospital of Sichuan University, Chengdu, Sichuan 610000, China. [6]Department of Outpatients, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China. [7]Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China. [8]Department of Gastroenterological Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China.
出处：
DOI： 10.1097/CM9.0000000000002277
ISSN：

关键词： Incidence Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis Outcome Prevalence

摘要：
The increasing burden of non-alcoholic fatty liver disease (NAFLD) worldwide imposes an emerging public health issue. We perform the current study to estimate the global prevalence, incidence, disease progression, and clinical outcomes of NAFLD.A systematic search was conducted in Medline, Embase, Web of Science, Google Scholar, and Cochrane CENTRAL that screened articles in English language published from January 2000 to December 2021. NAFLD prevalence, incidence, rate of disease progression, and outcomes were calculated with the DerSimonian-Laird random effects model with arcsine transformation.Our search identified 59,156 records, of which 578 studies fulfilled our inclusion criteria. The overall prevalence of NAFLD was 29.38% (95% confidence interval [CI] 28.09-30.69) regardless of the diagnostic techniques. Looking at the group in which the diagnosis was made by ultrasound exclusively, the pooled prevalence was 30.49% (95% CI 29.55-31.43). NAFLD has become more prevalent during the year 2011-2021 (31.63%, 95% CI 30.23-33.04) compared with year 2000-2010 (27.94%, 95% CI 26.23-29.69). The pooled estimation of non-alcoholic steatohepatitis prevalence was 8.26% (95% CI 1.13-21.01), 46.49% (95% CI 35.93-57.20), and 46.72% (95% CI 37.57-55.98) in general population, NAFLD patients, and severe/morbidly obese patients, respectively. Based on a total of 110,142 newly developed NAFLD patients, the pooled incident rate was estimated as 46.24 cases per 1000 person-years (95% CI 43.21-49.30). In patients with NAFLD, the incident rate of hepatocellular carcinoma was 1.46 (95% CI 0.90-2.03) cases per 1000 person-years. The overall pooled estimate of NAFLD related mortality was 23.91 (95% CI 13.55-37.18) death per 1000 person-years.The prevalence of NAFLD is increasing globally. It is contributing to poor clinical outcomes including hepatocellular carcinoma and death. Rising awareness and urgent actions are warranted to control the NAFLD pandemic across the globe.PROSPERO, No. CRD42020171104.Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

基金：
Department of Science and Technology of Sichuan Province (Nos. 2020YJ0237, 2021YFS0230, and 2020YFS0259) and China Postdoctoral Science Foundation (No. 2021M702340).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 2 区 医学
小类 | 2 区 医学：内科
最新[2023]版：
大类 | 3 区 医学
小类 | 3 区 医学：内科
第一作者：
第一作者机构： [1]Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China. [2]Laboratory of Thyroid and Parathyroid Diseases, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China. [3]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan 610000, China. [4]Respiratory Health Institute, Frontiers Science Center for Disease Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China.
通讯作者：
通讯机构： [8]Department of Gastroenterological Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China. [*1]Department of Gastroenterological Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China
推荐引用方式(GB/T 7714)：
Liu Jiaye,Tian Ye,Fu Xia,et al.Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis[J].Chinese Medical Journal.2022,135(14):1682-1691.doi:10.1097/CM9.0000000000002277.
APA：
Liu Jiaye,Tian Ye,Fu Xia,Mu Chunyang,Yao Menglin...&Li Zhihui.(2022).Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis.Chinese Medical Journal,135,(14)
MLA：
Liu Jiaye,et al."Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis".Chinese Medical Journal 135..14(2022):1682-1691

相关文献

[1]Editorial: Liver diseases and programmed cell death [2]Regional difference in the susceptibility of non-alcoholic fatty liver disease in China [3]Dysregulated m6A Modification Promotes Lipogenesis and Development of Non-alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. [4]Global liver disease burdens and research trends: Analysis from a Chinese perspective [5]Discovery of a Potent 9-Deazaxanthine-based Agent for the Treatment of Obesity-Related Non-alcoholic Fatty Liver Disease. [6]The hepato-ovarian axis: genetic evidence for a causal association between non-alcoholic fatty liver disease and polycystic ovary syndrome [7]Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases [8]Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis. [9]Psoralen Suppresses Lipid Deposition by Alleviating Insulin Resistance and Promoting Autophagy in Oleate-Induced L02 Cells [10]Filamin A is overexpressed in non-alcoholic steatohepatitis and contributes to the progression of inflammation and fibrosis

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号